Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    4130-CL-0201
Show Display Options
Rank Status Study
1 Active, not recruiting A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Condition: Colorectal Cancer
Interventions: Drug: Tivozanib;   Drug: Bevacizumab;   Drug: mFOLFOX6

Indicates status has not been verified in more than two years